FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:176-178 July 12, 2007 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Shiffman, M. L. PubMed Citation

Infection with hepatitis C virus (HCV) is a major worldwide cause of chronic liver disease, cirrhosis, and liver cancer, which together represent a chief global public health burden. Therapy has improved substantially since the introduction of interferon-alfa monotherapy in the late 1980s, when the response rate was less than 10%; now, combination therapy with peginterferon and ribavirin has a success rate of about 50%.^1,2 Much like the diverse outcomes of HCV infection, the response to treatment varies. Important factors associated with treatment response include the race, age, sex, weight, and biochemical and histologic characteristics of patients. However, viral genotype and, . . . [Full Text of this Article]

Source Information

From the Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.

This article has been cited by other articles:

• (2007). HCV Treatment -- How Short Can We Go?. JWatch Infect. Diseases 2007: 2-2 [Full Text]  
• (2007). Peginterferon plus Ribavirin for 16 or 24 Weeks for Genotype 2 or 3 HCV Infections. JWatch Gastroenterology 2007: 1-1 [Full Text]